Scholarlink

Background <p>The Triple A model has recently been developed and validated in essential thrombocythemia (ET) and polycythemia vera (PV).&#xa0;However, external validation in diverse populations remains unclear.</p> Purpose <p>The purpose of this study was to externally validate the Triple A prognostic model in a Turkish cohort of patients with ET and PV.</p> Methods <p>A retrospective analysis was conducted at two centers in Bursa, Türkiye, involving patients diagnosed with ET or PV under the World Health Organization (WHO) 2016/2022 criteria between 2014 and 2024.</p> Results <p>While the Triple A model has significantly separated the ET patients with a median follow-up of 47&#xa0;months (<i>p</i> = 0.015), no significant difference was observed in PV patients in terms of survival (<i>p</i> = 0.87). For thrombosis-free survival (TFS), Fine and Gray’s competing risk analysis showed a significant separation with the Triple A model in ET (<i>p</i> = 0.017).</p> Conclusion <p>While the Triple A model was validated as a practical prognostic tool in ET, it demonstrated limited utility in PV. Further multicenter studies are needed to refine risk stratification in PV.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Validation and interpretation of the Triple A model in Turkish myeloproliferative neoplasm patients with a focus on overall and thrombosis free survival

  • 期刊论文

  • 发表日期：

    2025年11月5日

查看全文
  • Mehmet Baysal,
  • Sevil Sadri,
  • Özgür Ömer Gül,
  • Elif Köse,
  • Serap Baysal,
  • Vildan Gursoy

摘要

Background

The Triple A model has recently been developed and validated in essential thrombocythemia (ET) and polycythemia vera (PV). However, external validation in diverse populations remains unclear.

Purpose

The purpose of this study was to externally validate the Triple A prognostic model in a Turkish cohort of patients with ET and PV.

Methods

A retrospective analysis was conducted at two centers in Bursa, Türkiye, involving patients diagnosed with ET or PV under the World Health Organization (WHO) 2016/2022 criteria between 2014 and 2024.

Results

While the Triple A model has significantly separated the ET patients with a median follow-up of 47 months (p = 0.015), no significant difference was observed in PV patients in terms of survival (p = 0.87). For thrombosis-free survival (TFS), Fine and Gray’s competing risk analysis showed a significant separation with the Triple A model in ET (p = 0.017).

Conclusion

While the Triple A model was validated as a practical prognostic tool in ET, it demonstrated limited utility in PV. Further multicenter studies are needed to refine risk stratification in PV.